Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide maps of p-STAT3 in PD-L1 silenced uveal melanoma cells and control cells

ABSTRACT: We performed CUT&Tag with anti-p-STAT3 antibodies in PD-L1 silenced uveal melanoma cells and control cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE202883 | GEO | 2023/04/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome-wide maps of p-STAT3 in PD-L1 silenced uveal melanoma cells and control cells

Project description:Genome-wide maps of p-STAT3 in PD-L1 silenced uveal melanoma cells and control cells

| PRJNA837592 | ENA

RNA sequencing of PD-L1 knock down in uveal melanoma cells

Project description:In order to study the mechanism of nuclear PD-L1 in uveal melanoma, we knocked down PD-L1 and applied RNA-seq and CUT&Tag to identify its target genes in uveal melanoma.

2023-04-04 | GSE202884 | GEO

Genome-wide maps of PD-L1 in uveal melanoma

Project description:Genome-wide maps of PD-L1 in uveal melanoma

| PRJNA835846 | ENA

Genome-wide maps of PD-L1 in uveal melanoma

Project description:For the first time, we investigated the role of nuclear PD-L1 in tumorgenesis of ocular melanoma.

2023-04-04 | GSE202394 | GEO

Transcriptome of primary and metastatic human melanoma with silenced STAT3

Project description:Transcriptome of primary and metastatic human melanoma with silenced STAT3

| PRJNA476058 | ENA

Objective to explore the mechanism of STAT3 regulating PD-L1 expression at transcriptional level after LIFR overexpression in pancreatic cancer cells.

Project description:The assays were performed in the standard manner to determine the influence of LIFR on the capacity of STAT3 (Cell signaling Technologyv, 124H6, cat#: 9139, 1µg) binding to DNA. Specific DNA fragments were obtained, purified, and subjected to PCR amplification using a NovoNGS® CUT&Tag 2.0 High-Sensitivity Kit (Novoprotein Scientific Inc), according to the protocol of the manufacturer. Berry Genomics Corporation (Beijing, China) was trusted to prepare the libraries and perform the sequencing.

2021-06-08 | GSE176309 | GEO

Genome-wide maps of H3K79me2 in uveal melanoma cells.

Project description:To investigate the role of H3K79me2 in tumorgenesis of uveal melanoma.

2022-01-04 | GSE181121 | GEO

DUSP2 dephosphorylates STAT3 at Y705 and S727 residues

Project description:In the related study, to determine whether DUSP2 definitively served as a phosphatase for STAT3, an in vitro phosphatase assay was used. Using S-tag beads, p-STAT3 was pulled down from IL-6 stimulated HEK293T cells transfected with STAT3-S-Tag. DUSP2 or control protein, which was purified from HEK293T cells transfected with DUSP2-FLAG or empty vector through extraction with anti-FLAG beads and elution with FLAG peptides, were incubated with p-STAT3-S-Tag-beads in phosphatase buffer. Then bound proteins were eluted and subjected to MS analysis. When compared with the control, incubation of STAT3 and DUSP2 led to dephosphorylation of two STAT3 residues that have been reported to promote its activity, namely tyrosine 705 and serine 727.

2015-10-13 | PXD002743 | Pride

RNA-Sequencing of Stat3 silenced oligodendrocyte progenitor cells.

Project description:We examine the role of Stat3 in oligodendrocyte progenitor cells and determine that direct binding of Stat3 to the Etv6 promoter, and subsequent upregulation, in part, promotes differentiation.

2017-06-07 | GSE99709 | GEO

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.

Project description:Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized.Fifty-eight patients with stage IV uveal melanoma received PD-1 or PD-1 ligand (PD-L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was performed every 12 weeks and at the investigators' discretion. Safety and clinical efficacy outcomes, including the best overall response, progression-free survival (PFS), and overall survival (OS), were retrospectively determined.Of 56 eligible patients, 48 (86%) had received prior therapy, and 35 (63%) had received treatment with ipilimumab. Three patients had an objective response to ipilimumab, and 8 had stable disease as their best response. Thirty-eight patients (68%) received pembrolizumab, 16 (29%) received nivolumab, and 2 (4%) received atezolizumab. Objective tumor responses were observed in 2 patients for an overall response rate of 3.6% (95% confidence interval [CI], 1.8%-22.5%). Stable disease (?6 months) was observed in 5 patients (9%). The median PFS was 2.6 months (95% CI, 2.4-2.8 months), and the median OS was 7.6 months (95% CI, 0.7-14.6 months). There was no association between prior treatment with ipilimumab or liver-directed therapy and PFS or OS. Treatment was well tolerated, and only 1 patient discontinued treatment because of toxicity.PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Clinical trial enrollment should be prioritized in this population. Cancer 2016;122:3344-3353. © 2016 American Cancer Society.

| S-EPMC5767160 | biostudies-other

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data